These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18416310)

  • 1. Histone deacetylase inhibitors from microorganisms: the Astellas experience.
    Masuoka Y; Shindoh N; Inamura N
    Prog Drug Res; 2008; 66():335, 337-59. PubMed ID: 18416310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma.
    VanderMolen KM; McCulloch W; Pearce CJ; Oberlies NH
    J Antibiot (Tokyo); 2011 Aug; 64(8):525-31. PubMed ID: 21587264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
    Saijo K; Imamura J; Narita K; Oda A; Shimodaira H; Katoh T; Ishioka C
    Cancer Sci; 2015 Feb; 106(2):208-15. PubMed ID: 25492515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From discovery to the coming generation of histone deacetylase inhibitors.
    Yoshida M; Matsuyama A; Komatsu Y; Nishino N
    Curr Med Chem; 2003 Nov; 10(22):2351-8. PubMed ID: 14529478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
    Pojani E; Barlocco D
    Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5''-epi-spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity.
    Narita K; Kikuchi T; Watanabe K; Takizawa T; Oguchi T; Kudo K; Matsuhara K; Abe H; Yamori T; Yoshida M; Katoh T
    Chemistry; 2009 Oct; 15(42):11174-86. PubMed ID: 19760730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities.
    Wang C; Henkes LM; Doughty LB; He M; Wang D; Meyer-Almes FJ; Cheng YQ
    J Nat Prod; 2011 Oct; 74(10):2031-8. PubMed ID: 21793558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A.
    Crabb SJ; Howell M; Rogers H; Ishfaq M; Yurek-George A; Carey K; Pickering BM; East P; Mitter R; Maeda S; Johnson PW; Townsend P; Shin-ya K; Yoshida M; Ganesan A; Packham G
    Biochem Pharmacol; 2008 Aug; 76(4):463-75. PubMed ID: 18611394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total synthesis of bicyclic depsipeptides spiruchostatins C and D and investigation of their histone deacetylase inhibitory and antiproliferative activities.
    Narita K; Fukui Y; Sano Y; Yamori T; Ito A; Yoshida M; Katoh T
    Eur J Med Chem; 2013 Feb; 60():295-304. PubMed ID: 23313638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis.
    Kwon HJ; Kim MS; Kim MJ; Nakajima H; Kim KW
    Int J Cancer; 2002 Jan; 97(3):290-6. PubMed ID: 11774279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Synthetic Study on Bicyclic Depsipeptides Containing an Intramolecular Disulfide Bond].
    Narita K
    Yakugaku Zasshi; 2022; 142(9):917-926. PubMed ID: 36047217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.
    Yurek-George A; Cecil AR; Mo AH; Wen S; Rogers H; Habens F; Maeda S; Yoshida M; Packham G; Ganesan A
    J Med Chem; 2007 Nov; 50(23):5720-6. PubMed ID: 17958342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase as a new target for cancer chemotherapy.
    Yoshida M; Furumai R; Nishiyama M; Komatsu Y; Nishino N; Horinouchi S
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S20-6. PubMed ID: 11587361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).
    Harrison SJ; Bishton M; Bates SE; Grant S; Piekarz RL; Johnstone RW; Dai Y; Lee B; Araujo ME; Prince HM
    Epigenomics; 2012 Oct; 4(5):571-89. PubMed ID: 23130838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.
    Sasakawa Y; Naoe Y; Noto T; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
    Biochem Pharmacol; 2003 Sep; 66(6):897-906. PubMed ID: 12963476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
    Xiao JJ; Huang Y; Dai Z; Sadée W; Chen J; Liu S; Marcucci G; Byrd J; Covey JM; Wright J; Grever M; Chan KK
    J Pharmacol Exp Ther; 2005 Jul; 314(1):467-75. PubMed ID: 15833893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
    Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors.
    Saijo K; Katoh T; Shimodaira H; Oda A; Takahashi O; Ishioka C
    Cancer Sci; 2012 Nov; 103(11):1994-2001. PubMed ID: 22924958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.